Glipizide 10 milligrams. Glipizide sensitizes the beta cells of pancreatic islets of Langerhans insulin response, meaning that more insulin is released in response to glucose than would be without glipizide ingestion. Glipizide acts by partially blocking potassium channels among beta cells of pancreatic islets of Langerhans. By blocking potassium channels, the cell depolarizes, which results in the opening of voltage-gated calcium channels. The resulting calcium influx encourages insulin release from beta cells. Glipizide Glipizide is an oral rapid- and short-acting anti-diabetic medication from the sulfonylurea class. It is classified as a second-generation sulfonylurea, which means that it undergoes enterohepatic circulation. Second-generation
Paul Langerhans Paul Langerhans Paul Langerhans (25 July 1847 – 20 July 1888) was a German pathologist, physiologist and biologist, credited with the discovery of the cells that secrete insulin, named after him as the islets of Langerhans. Langerhans was born in Berlin on 25 July 1847, the son of a physician. He later entered the renowned Graues Kloster in the same city. Due to his outstanding performance he was exempted from the final oral examinations. He began his medical studies at the University of Jena and completed them in Berlin. In February 1869, he presented a thesis entitled “Contributions to the